Testosterone Levels in Men with Chronic Migraine by Shields, Lisa B. E. et al.
University of Kentucky
UKnowledge
Markey Cancer Center Faculty Publications Cancer
6-19-2019
Testosterone Levels in Men with Chronic Migraine





University of Kentucky, brent.shelton@uky.edu
Brian M. Plato
Norton Healthcare
Right click to open a feedback form in a new tab to let us know how this document benefits you.
Follow this and additional works at: https://uknowledge.uky.edu/markey_facpub
Part of the Hormones, Hormone Substitutes, and Hormone Antagonists Commons, and the
Neurology Commons
This Article is brought to you for free and open access by the Cancer at UKnowledge. It has been accepted for inclusion in Markey Cancer Center
Faculty Publications by an authorized administrator of UKnowledge. For more information, please contact UKnowledge@lsv.uky.edu.
Repository Citation
Shields, Lisa B. E.; Seifert, Tad; Shelton, Brent J.; and Plato, Brian M., "Testosterone Levels in Men with Chronic Migraine" (2019).
Markey Cancer Center Faculty Publications. 144.
https://uknowledge.uky.edu/markey_facpub/144
Testosterone Levels in Men with Chronic Migraine
Notes/Citation Information
Published in Neurology International, v. 11, no. 2, 8079, p. 18-20.
©Copyright L.B.E. Shields et al., 2019
This work is licensed under a Creative Commons Attribution NonCommercial 4.0 License (CC BY-NC 4.0).
Digital Object Identifier (DOI)
https://doi.org/10.4081/ni.2019.8079
This article is available at UKnowledge: https://uknowledge.uky.edu/markey_facpub/144
                             Neurology International 2019; volume 11:8079
Testosterone levels in men 
with chronic migraine
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Abstract 
Chronic migraine is a frequent and
debilitating condition affecting 14% of the
general population. This prospective obser-
vational pilot study investigated whether
men with chronic migraine have lower than
expected total serum testosterone levels. We
identified 14 men ages 26-51 at our
Institution who fulfilled the ICHD-3b crite-
ria for chronic migraine and obtained serum
total testosterone levels. The mean total
testosterone level in our 14 patients was 322
ng/dL (range: 120-542 ng/dL) which is in
the lower 5% of the reference range for our
laboratory (300-1080 ng/dL). Men with
chronic migraine had lower total testos-
terone levels compared to published age-
matched normative median values by a
median difference of 62 ng/dL (P=0.0494).
This finding suggests that hypothalamic
regulation is altered in patients with chronic
migraine. Further studies are warranted to
determine whether testosterone supplemen-
tation in men with chronic migraine reduces
the number of headaches or the associated
symptoms of hypogonadism.
Introduction
Migraine is a common, multifactorial,
disabling primary headache disorder.1,2
According to the International
Classification of Headache Disorders, 3rd
edition (beta version), chronic migraine
refers to a headache occurring on 15 or
more days per month for more than 3
months which has the features of migraine
on at least 8 days per month.2 According to
the National Health Interview Survey in
2012, the overall prevalence of migraine or
severe headache is 14.2% in the United
States, with 19.1% of females and 9.0% of
males affected with substantial variations
depending on age.3 Migraine ranked as the
third most common cause of disability
worldwide in individuals under 50 as
reported by the Global Burden of Disease
Survey 2015.4 Migraines are considered to
involve the hypothalamus, brainstem, and
cortex which regulates autonomic, affec-
tive, cognitive, and sensory functions.1
Chronic migraine may affect hypothalamic
hormonal secretion. Many men with chron-
ic migraine exhibit symptoms that are fre-
quently seen with hypogonadism
(depressed mood, reduced energy, difficulty
concentrating). 
Positron emission tomography (PET)
has shown hypothalamic activation in spon-
taneous migraine attacks which persists
after headache relief by sumatriptan.5,6
Attention has focused on the function of the
hypothalamus in circadian rhythms, pain
control coordinating the activity of the sym-
pathetic and parasympathetic nervous sys-
tems, and in maintaining homeostasis.1,5,7
In addition, the hypothalamus is integrally
involved with the body’s responses to
stress.7 The hypothalamus secretes
gonadotropin-releasing hormone (GnRH)
which stimulates the anterior pituitary gland
to release luteinizing hormone (LH) from
the gonadotrophs.8 The receptors for LH are
located on Leydig cells in the testis which
synthesize testosterone following LH stim-
ulation.8 Figure 1 depicts the hypothalamic
regulation of testosterone.  
There are no reports known to the
authors on the effect that chronic migraine
may have on testosterone levels in men. We
investigated whether men with chronic
migraine have lower than expected total
serum testosterone levels. In this prospec-
tive pilot study, we present our findings per-
taining to the interaction between chronic
migraine and testosterone levels. We also
discuss the impact of chronic migraine on
the regulation of the hypothalamo-pituitary-
gonadal axis.
Materials and Methods 
Patient population
Under an institutional review board
(IRB) approved protocol, we prospectively
identified 14 men who fulfilled the ICHD-
3b criteria for chronic migraine without opi-
oid or barbiturate overuse at our Institution.
These patients were evaluated by a neurolo-
gist at our Institution’s outpatient clinic in a
metropolitan community. All men obtained
serum total testosterone levels. These val-
ues were compared to the local laboratory
normal values and to published age-
matched controls.9
Statistical analysis
Data are presented in listings and sum-
marized as either mean (SD) or median
(interquartile range: 25th %-tile & 75th %-
tile). To test whether the testosterone distri-
bution amongst those men with migraines
differed from a control population distribu-
tion, the median testosterone from a pub-
lished age-specific control population was
matched to the age-specific testosterone
level for the 14 migraine subjects.9 To
assess whether these age-matched groups
differed, Wilcoxon Signed Rank test was
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used to test for the testosterone distribution
difference. An a-priori two-sided signifi-
cance level of 5% was used to interrogate
any observed difference. 
Results 
A total of 14 men fulfilled the criteria
for inclusion. The mean age was 36.1 years
(range: 26-51 years). The local laboratory
normal range for total testosterone was 300-
1080 ng/dL. Table 1 illustrates the total
testosterone levels of migraine patients
compared to published age-matched con-
trols. The mean total testosterone level in
the 14 patients with chronic migraine was
322 ng/dL (range: 120-542 ng/dL). 
For published age-matched controls, the
mean total testosterone level was 384 ng/dL
(SD=10.3). Six males (43%) had testos-
terone levels below the minimum of the
normal local laboratory range. Men with
chronic migraine had lower total testos-
terone levels compared to published age-
matched controls by a median difference of
62.0 ng/dL (interquartile range of 0.34 to
130). The Wilcoxon Signed rank statistic
revealed a statistically significant difference
between the two distributions (P=0.0494).
Discussion
In our pilot study, men with
chronic migraine had statistically signifi-
cant lower total testosterone levels com-
pared to an age-matched normative popula-
tion, suggesting that hypothalamic regula-
tion is altered in patients with chronic
migraine. We propose that the suppression
of the hypothalamic pituitary axis as a result
of chronic migraine inhibits the release of
GnRH resulting in secondary hypogo-
nadism. A host of studies have investigated
the pathophysiology of the hypothalamus in
both cluster headache10 and chronic
migraine,1,5-7,11 however, a paucity of stud-
ies have explored the interaction between
testosterone levels and chronic migraine,
tension type headache (TTH), and cluster
headache.12,13 It has been suggested that
both male and female sex hormones could
influence the course of primary headaches,
specifically, tension-type headache,
migraine, and cluster headache.14 Romiti
and colleagues studied plasma testosterone
levels in cluster headache and non-cluster
headache controls.13 Plasma testosterone
levels were significantly lower during the
cluster attack and were within the reference
limits in the remission period of episodic
cluster headache.13 These authors suggest
that a decrease of plasma testosterone levels
in episodic cluster headache should be con-
sidered in relation to disordered rapid eye
movement (REM) sleep in cluster
headache.   
The present study and that of Romiti et
al. highlighted testosterone levels in
migraine and cluster headache,
respectively.13 Both studies reported that
testosterone levels were significantly lower
in the headache disorder group compared to
controls. We demonstrated that men with
chronic migraine had lower total testos-
terone levels compared to their age-
matched control by a median difference of
62 ng/dL (interquartile range of 0.34 to
130). In addition, there was a statistically
significant difference between the two dis-
tributions (P=0.0494). Six males (43%) had
testosterone levels below the minimum of
the normal local laboratory range. Of note,
the mean total testosterone level in our 14
patients with chronic migraine was 322
ng/dL which is in the lower 5% of the refer-
ence range for our laboratory (300-1080
ng/dL). This finding supports that testos-
terone levels are very low in migraine
patients.  Abnormality of the hypothalamus-
pituitary-gonadal axis is believed to be
involved in the pathogenesis of migraine.15
In Li and colleagues’ study of the levels of
HPG axis hormones serum FSH, LH, estra-
diol, progesterone, testosterone, prolactin,
and GnRH, they reported that these hor-
mones were abnormal in migraineurs and
were associated with migraine-related clini-
cal characteristics.15
Hypogonadism refers to “a clinical syn-
drome that results from failure of the testis
to produce physiological levels of testos-
terone (androgen deficiency) and a normal
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Table 1. Total testosterone levels of migraine patients compared to published age-matched controls.
Age                      Total testosterone of                                 Normal for reference                                Total testosterone of published
                        migraine patients (ng/dL)                               lab (1=yes;0=no)                                   age-matched controls (ng/dL)*
26                                                     406                                                                                     1                                                                                                406
27                                                     428                                                                                     1                                                                                                403
30                                                     120                                                                                     0                                                                                                392
32                                                     434                                                                                     1                                                                                                386
33                                                     270                                                                                     0                                                                                                383
33                                                     324                                                                                     1                                                                                                383
34                                                     378                                                                                     1                                                                                                383
35                                                     268                                                                                     0                                                                                                380
37                                                     542                                                                                     1                                                                                                378
38                                                     360                                                                                     1                                                                                                378
40                                                     230                                                                                     0                                                                                                375
42                                                     310                                                                                     1                                                                                                375
48                                                     196                                                                                     0                                                                                                375
51                                                     245                                                                                     0                                                                                                375
Normal Testosterone Range (Local Reference Lab): 300-1080 ng/dL. *See Kelsey et al. 2014.9











number of spermatozoa due to disruption of
one or more levels of the hypothalamic-
pituitary-testicular axis”.16 Hypogonadal
symptoms include diminished libido,
fatigue, poor concentration, erectile dys-
function, and depressed mood in the setting
of low serum testosterone levels.17 Many
men with chronic migraine exhibit symp-
toms that are frequently seen with hypogo-
nadism, specifically, depressed mood,
reduced energy, and difficulty concentrat-
ing. Testosterone supplementation has been
shown to be beneficial in improving both
hypogonadal symptoms and serum total
testosterone levels.16,17 Testosterone thera-
py in hypogonadal men has been shown to
be highly effective and safe for improving
lower urinary tract symtpoms, cardiometa-
bolic risk, and major adverse cardiovascular
events18 as well as urinary and sexual func-
tion and quality of life.19 Testosterone
serves as a neuroprotective agent,20 sug-
gesting a valuable role in the treatment of
chronic migraine. Continuous testosterone
has also been reported as beneficial in
reducing the severity of migraines in both
pre- and post-menopausal women.21 These
studies demonstrate that testosterone effec-
tively treats migraine headaches in both
men and women and that low testosterone is
likely causal and not the result of migraines. 
The strength of the present study is the
prospective evaluation of the possible role
of testosterone in migraine headaches as it
is far less studied than estrogen/proges-
terone. Our study is limited by its small
sample size. Prospective, randomized stud-
ies with a larger sample size are warranted
to permit generalizability of our results. 
Conclusions
In this pilot study, men with chronic
migraine had statistically significant lower
total testosterone levels compared to an
age-matched normative population. Further
investigation is necessary to determine
whether testosterone supplementation in
men with chronic migraine reduces either
the number of headache days per month or
the accompanying symptoms of hypogo-
nadism.
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